Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis

作者：Shuting Han, Qingyuan Zhuang, Jianbang Chiang, Sze Huey Tan, Gail Wan Ying Chua, Conghua Xie, Melvin L.K. Chua, Yu Yang Soon, Valerie Shiwen Yang · 发表于：BMJ Open · 年份：2022 · DOI：10.1136/bmjopen-2020-044661 · 被引用次数：65 · 研究领域：COVID-19 and healthcare impacts、COVID-19 Clinical Research Studies、Lymphadenopathy Diagnosis and Analysis

BACKGROUND: The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA). METHODS: Systematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019-31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients. RESULTS: =97.69%, p<0.001). The pooled RR of death was 1.44 (95% CI 1.19 to 1.76) between patients with cancer and the general population with COVID-19 infection. The pooled RR of severe outcome was 1.49 (95% CI 1.18 to 1.87) between cancer and general COVID-19 patients. The presence of lung cancer and stage IV cancer did not result in significantly increased RR of severe outcome. Among the available IPD, only age and gender were associated wi...